mTOR as Mediator of Insulin Sensitivity Study
ConditionInsulin Sensitivity
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age22-35
SponsorUniversity of Copenhagen
About this trial
The study investigates the role of mTOR in mediating enhancement of muscle insulin sensitivity following a single bout of exercise.
This will be investigated in young healthy male subjects by administering the pharmacological mTOR inhibitor Rapamycin in a crossover blinded experimental setup known to enhance muscle insulin sensitivity following one-legged knee-extensor exercise.
Eligibility criteria
Qualifiers
Healthy persons (no known disease) without diabetes in the family
No use of medications
Non-smokers
Men
Disqualifiers
Women
Physical activity (e.g., running, cycling, fitness, etc.) above 6 hours a week.
Persons who show signs of metabolic diseases, hematologic diseases, reduced liver function, human immunodeficiency virus (HIV), hepatitis, thyroid diseases or other signs of disease that may affect the outcome of the study or the study subject's wellbeing will be excluded.
Acute sickness less than 2 weeks prior to study start.
Trial design
Treatments tested in this trial
- Exercise
- Insulin infusion
- Placebo
- Rapamycin
Treatment groups
10 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Copenhagen
Lead sponsor
Danish Diabetes Academy
Collaborator
Source ClinicalTrials.gov